Device Trial Radar · NCT07947589
ToeFX Light Therapy for Chronic Venous Leg Ulcers
Last checked: Nov 19, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
20
Planned (sponsor's estimate)
Start
Nov 15, 2026
Primary completion
Oct 31, 2027
Study completion Oct 31, 2027
Sponsor
- Lead sponsor
- Dr. Ahmed KayssiAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Nov 19, 2026
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Device feasibility
- FDA-regulated device
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Chronic venous leg ulcers can be painful and prone to infection. They can significantly limit a patient's function, mobility and quality of life. A major contributor to delayed ulcer healing is persistent bacteria. Treatments that can penetrate the bacteria's protective outer shield to kill and clear the bacteria are important for helping ulcers heal more quickly. The purpose of this pilot study is to test a topical study treatment (called ClearToe Serum®) plus two types of light (red and blue-purple light) in the treatment of chronic venous ulcers. This is an open-label single-arm pilot study. All participants will receive the test treatment as well as standard or care treatment for their chronic venous ulcer. Participants will receive study treatments one per week for up to 12 weeks, or until their ulcer is healed. The main objectives are to assess adherence to the one-per-week study treatments, and to note any study device-related, study treatment-related, or serious adverse events, or adverse events that lead to stopping study treatment.
Conditions
- Venous Leg Ulcer (VLU)
- Venous Leg Ulcers (VLUs)
- Wound Closure
- Wound Care
Interventions
Non-thermal photodynamic therapyDevice
Non-thermal photodynamic therapy platform that combines a methylene-blue-based photosensitizer ( ClearToe® serum) with 660 nm light irradiation
Primary outcomes
What the sponsor says the trial is designed to measure.
- Treatment adherenceTime frame: Baseline through Visit 12/ end of treatment (up to 12 weeks)
- Safety: Adverse EventsTime frame: Baseline through Healing Confirmation Visit (up to 14 weeks)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
East Toronto Vascular Clinic
Toronto, Ontario, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.